| ￥500 | |
| RP30971-1 | |
|
|
|
|
|
|
|
|
|
The Survivin peptide (LMLGEFLKL), also known as BIRC5, is a member of the apoptosis inhibitor protein family. It is overexpressed in most human cancers but is rarely found in normal tissues. This peptide is significant in cancer therapy as it can stimulate cytotoxic T lymphocyte (CTL) responses, which are crucial for immune-based treatments. The peptide is used in various applications, including vaccine development for metastatic melanoma, where specific T cells have been detected among peripheral blood mononuclear cells (PBMCs) of vaccinated patients. |
| Synonyms | Survivin Peptide (LMLGEFLKL) |
| Description | Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. |
| Sequence |
{Leu}{Met}{Leu}{Gly}{Glu}{Phe}{Leu}{Lys}{Leu} |
| Sequence Shortening | LMLGEFLKL |
| Molecular Formula | C51H86N10O12S |
| Molecular Weight | 1063.37 |
| Length | 9 |
| Purity | >95% |
| Solubility | Soluble in HCOOH under 1mg/ml |
| Form | Lyophilized |
| Storage | Store at -20°C. Keep tightly closed. Store in a cool dry place. |
